ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This article will focus on the development of tyrosine kinase inhibitors (TKIs) in CML, as well as the emerging specifically targeting the ABL myristoyl pocket (STAMP) inhibitors.